Movement Alert｜WuXi XDC Rises 3.01% in Regular Trading, CXO Sector Continues Rally Amid Buyback Wave and Analyst Endorsement

Market Focus

Jun 25

On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session, extending a multi-day rally.

On the news front, BOCOM International recently issued a research report identifying WuXi XDC as a top pick with strong investment value within the high-growth bioconjugate CRDMO track. The broader CXO sector has continued to strengthen, with WuXi AppTec up 2.33%, WuXi Biologics up 1.6%, and Insilico Medicine up 9.0% on the same day, forming a sector resonance effect. In addition, the pharmaceutical sector has seen a wave of buybacks and insider purchases since Q2, with over 100 biopharma companies across A-shares and H-shares disclosing repurchase plans, with innovative drug companies serving as the core driving force behind this trend.

Furthermore, WuXi XDC's subsidiary Dongyao Pharma signed a process development and manufacturing services agreement with WuXi Biologics on June 16, covering 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1164308683"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164308683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164308683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 11:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164308683","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Rises 3.01% in Regular Trading, CXO Sector Continues Rally Amid Buyback Wave and Analyst Endorsement","media":"Market Focus","content":"<p><p>On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session, extending a multi-day rally.</p><p>On the news front, BOCOM International recently issued a research report identifying WuXi XDC as a top pick with strong investment value within the high-growth bioconjugate CRDMO track. The broader CXO sector has continued to strengthen, with WuXi AppTec up 2.33%, WuXi Biologics up 1.6%, and Insilico Medicine up 9.0% on the same day, forming a sector resonance effect. In addition, the pharmaceutical sector has seen a wave of buybacks and insider purchases since Q2, with over 100 biopharma companies across A-shares and H-shares disclosing repurchase plans, with innovative drug companies serving as the core driving force behind this trend.</p><p>Furthermore, WuXi XDC's subsidiary Dongyao Pharma signed a process development and manufacturing services agreement with WuXi Biologics on June 16, covering 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Rises 3.01% in Regular Trading, CXO Sector Continues Rally Amid Buyback Wave and Analyst Endorsement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Rises 3.01% in Regular Trading, CXO Sector Continues Rally Amid Buyback Wave and Analyst Endorsement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 11:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session, extending a multi-day rally.</p><p>On the news front, BOCOM International recently issued a research report identifying WuXi XDC as a top pick with strong investment value within the high-growth bioconjugate CRDMO track. The broader CXO sector has continued to strengthen, with WuXi AppTec up 2.33%, WuXi Biologics up 1.6%, and Insilico Medicine up 9.0% on the same day, forming a sector resonance effect. In addition, the pharmaceutical sector has seen a wave of buybacks and insider purchases since Q2, with over 100 biopharma companies across A-shares and H-shares disclosing repurchase plans, with innovative drug companies serving as the core driving force behind this trend.</p><p>Furthermore, WuXi XDC's subsidiary Dongyao Pharma signed a process development and manufacturing services agreement with WuXi Biologics on June 16, covering 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1164308683","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164308683","pubTimestamp":1782356545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向提示|药明XDC常规交易涨3.01%CXO板块在回购潮和分析师背书中继续反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On June 25, WuXi XDC (02268.HK) rose 3.01% in regular trading, trading at HKD 55.0/share, with turnover of HKD 152 million. The gain follows a surge of over 10% in the previous trading session, extending a multi-day rally.On the news front, BOCOM International recently issued a research report identifying WuXi XDC as a top pick with strong investment value within the high-growth bioconjugate CRDMO track. The broader CXO sector has continued to strengthen, with WuXi AppTec up 2.33%, WuXi Biologics up 1.6%, and Insilico Medicine up 9.0% on the same day, forming a sector resonance effect. In addition, the pharmaceutical sector has seen a wave of buybacks and insider purchases since Q2, with over 100 biopharma companies across A-shares and H-shares disclosing repurchase plans, with innovative drug companies serving as the core driving force behind this trend.Furthermore, WuXi XDC's subsidiary Dongyao Pharma signed a process development and manufacturing services agreement with WuXi Biologics on June 16, covering 10 batches of monoclonal antibody intermediates totaling RMB 19 million, aimed at deepening technical know-how and enhancing process capabilities.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}